You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFlunitrazepam
Accession NumberDB01544
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionA benzodiazepine with pharmacologic actions similar to those of diazepam that can cause anterograde amnesia. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug. [PubChem]
Structure
Thumb
Synonyms
Flunitrazepamum
Rohypnol
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
HipnosedonRoche
HypnodormAlphapharm
NarcozepRoche
RohypnolRoche
RoipnolRoche
Brand mixturesNot Available
SaltsNot Available
Categories
UNII620X0222FQ
CAS number1622-62-4
WeightAverage: 313.2832
Monoisotopic: 313.08626947
Chemical FormulaC16H12FN3O3
InChI KeyInChIKey=PPTYJKAXVCCBDU-UHFFFAOYSA-N
InChI
InChI=1S/C16H12FN3O3/c1-19-14-7-6-10(20(22)23)8-12(14)16(18-9-15(19)21)11-4-2-3-5-13(11)17/h2-8H,9H2,1H3
IUPAC Name
5-(2-fluorophenyl)-1-methyl-7-nitro-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
CN1C2=C(C=C(C=C2)[N+]([O-])=O)C(=NCC1=O)C1=CC=CC=C1F
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Halobenzene
  • Fluorobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Tertiary carboxylic acid amide
  • Organic nitro compound
  • Tertiary amine
  • Organic nitrite
  • C-nitro compound
  • Lactam
  • Ketimine
  • Carboxamide group
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Imine
  • Carbonyl group
  • Amine
  • Organic zwitterion
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor short-term treatment of severe insomnias, that are not responsive to other hypnotics.
PharmacodynamicsFlunitrazepam is a powerful hypnotic drug that is a benzodiazepine derivative. It has powerful hypnotic, sedative, anxiolytic, and skeletal muscle relaxant properties. The drug is sometimes used as a date rape drug. In the United States, the drug has not been approved by the Food and Drug Administration for medical use, and is considered to be an illegal drug. It has however been approved in the United Kingdom and other countries.
Mechanism of actionBenzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
Related Articles
Absorption50% (suppository) and 64-77% (oral)
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half life18-26 hours
ClearanceNot Available
ToxicitySymptoms of overdose include confusion, coma, impaired coordination, sleepiness, and slowed reaction time.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9922
Blood Brain Barrier+0.973
Caco-2 permeable+0.5257
P-glycoprotein substrateSubstrate0.6717
P-glycoprotein inhibitor INon-inhibitor0.6428
P-glycoprotein inhibitor IINon-inhibitor0.9094
Renal organic cation transporterNon-inhibitor0.713
CYP450 2C9 substrateNon-substrate0.7621
CYP450 2D6 substrateNon-substrate0.8932
CYP450 3A4 substrateSubstrate0.725
CYP450 1A2 substrateNon-inhibitor0.5691
CYP450 2C9 inhibitorNon-inhibitor0.5163
CYP450 2D6 inhibitorNon-inhibitor0.8776
CYP450 2C19 inhibitorInhibitor0.5957
CYP450 3A4 inhibitorInhibitor0.5626
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5555
Ames testAMES toxic0.9108
CarcinogenicityNon-carcinogens0.7209
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8125 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9869
hERG inhibition (predictor II)Non-inhibitor0.8074
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point166-167 °CKariss, J. and Newmark, H.L.; U.S. Patent 3,116,203; December 31, 1963; assigned to Hoffmann-la Roche Inc.
 Kariss, J. and Newmark, H.L.; US. Patent 3,123,529; March 3,1964; assigned to Hoffmann-La Roche Inc. 
Keiler, O., Steiger, N. and Sternbach, L.H.; U.S. Patent 3,203,990; August 31, 1965; assigned to Hoffmann-La Roche Inc.
logP2.06HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00858 mg/mLALOGPS
logP2.2ALOGPS
logP2.55ChemAxon
logS-4.6ALOGPS
pKa (Strongest Basic)1.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area78.49 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity82.55 m3·mol-1ChemAxon
Polarizability29.6 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-01p9-2393000000-5d873203e4acf1211838View in MoNA
References
Synthesis Reference

Kariss, J. and Newmark, H.L.; U.S. Patent 3,116,203; December 31, 1963; assigned to Hoffmann-la Roche Inc.
 Kariss, J. and Newmark, H.L.; US. Patent 3,123,529; March 3,1964; assigned to Hoffmann-La Roche Inc. 
Keiler, O., Steiger, N. and Sternbach, L.H.; U.S. Patent 3,203,990; August 31, 1965; assigned to Hoffmann-La Roche Inc.

General References
  1. Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. [PubMed:2883820 ]
  2. Robertson MD, Drummer OH: Postmortem drug metabolism by bacteria. J Forensic Sci. 1995 May;40(3):382-6. [PubMed:7782744 ]
  3. Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [PubMed:2570451 ]
  4. Usami N, Yamamoto T, Shintani S, Ishikura S, Higaki Y, Katagiri Y, Hara A: Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5. [PubMed:11995921 ]
  5. Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8. [PubMed:17287588 ]
External Links
ATC CodesN05CD03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Flunitrazepam can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Flunitrazepam.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Flunitrazepam.
AminophyllineThe therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Aminophylline.
AmiodaroneThe metabolism of Flunitrazepam can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Flunitrazepam.
AmoxapineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Amperozide.
AprepitantThe serum concentration of Flunitrazepam can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Flunitrazepam.
ArmodafinilThe metabolism of Flunitrazepam can be decreased when combined with Armodafinil.
ArticaineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Asenapine.
AtazanavirThe metabolism of Flunitrazepam can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Flunitrazepam can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Azaperone.
AzelastineFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Flunitrazepam.
AzithromycinThe metabolism of Flunitrazepam can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Flunitrazepam.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Flunitrazepam.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Benzyl alcohol.
BexaroteneThe serum concentration of Flunitrazepam can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Flunitrazepam can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Flunitrazepam can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Flunitrazepam can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.
BrimonidineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Flunitrazepam.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Flunitrazepam.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Flunitrazepam.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Flunitrazepam.
ButacaineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Flunitrazepam.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Flunitrazepam.
CaffeineThe metabolism of Flunitrazepam can be decreased when combined with Caffeine.
CapecitabineThe metabolism of Flunitrazepam can be decreased when combined with Capecitabine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Flunitrazepam.
CarbinoxamineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Flunitrazepam.
CarisoprodolThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Carisoprodol.
CeritinibThe serum concentration of Flunitrazepam can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Flunitrazepam can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Flunitrazepam.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Flunitrazepam.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Flunitrazepam.
ChlorphenamineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Flunitrazepam.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Flunitrazepam.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Flunitrazepam can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Flunitrazepam can be decreased when combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Flunitrazepam.
CitalopramThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Citalopram.
CitalopramThe metabolism of Flunitrazepam can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Flunitrazepam can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Flunitrazepam can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Clonidine.
ClopidogrelThe metabolism of Flunitrazepam can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flunitrazepam.
ClotrimazoleThe metabolism of Flunitrazepam can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Flunitrazepam.
CobicistatThe metabolism of Flunitrazepam can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Flunitrazepam.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Flunitrazepam.
ConivaptanThe serum concentration of Flunitrazepam can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Flunitrazepam can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flunitrazepam.
CyclosporineThe metabolism of Flunitrazepam can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Flunitrazepam can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Flunitrazepam can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flunitrazepam.
DapoxetineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dapoxetine.
DarunavirThe metabolism of Flunitrazepam can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Flunitrazepam can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Flunitrazepam can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Flunitrazepam can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Flunitrazepam.
DesipramineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Detomidine.
DexamethasoneThe serum concentration of Flunitrazepam can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Flunitrazepam.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Flunitrazepam.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Flunitrazepam.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Flunitrazepam.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Flunitrazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Flunitrazepam can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Flunitrazepam.
DihydromorphineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dihydromorphine.
DiltiazemThe metabolism of Flunitrazepam can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Flunitrazepam.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Flunitrazepam.
DoramectinThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Doxepin.
DoxorubicinThe metabolism of Flunitrazepam can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Flunitrazepam can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.
DoxylamineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.
DronedaroneThe metabolism of Flunitrazepam can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Flunitrazepam.
DrotebanolThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Flunitrazepam.
DyphyllineThe therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Dyphylline.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Flunitrazepam.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Flunitrazepam can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Flunitrazepam.
EntacaponeThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Entacapone.
EnzalutamideThe serum concentration of Flunitrazepam can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Flunitrazepam can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Flunitrazepam can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Flunitrazepam can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Flunitrazepam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Flunitrazepam.
EthanolFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Flunitrazepam.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flunitrazepam.
EthosuximideThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Flunitrazepam.
EtidocaineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Flunitrazepam.
EtoperidoneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Flunitrazepam.
EtravirineThe serum concentration of Flunitrazepam can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Flunitrazepam.
FenfluramineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Flunitrazepam.
FexofenadineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Flibanserin.
FloxuridineThe metabolism of Flunitrazepam can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Flunitrazepam can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Flunarizine.
FluorouracilThe metabolism of Flunitrazepam can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fluoxetine.
FluoxetineThe metabolism of Flunitrazepam can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Flunitrazepam.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flunitrazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Flunitrazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Flunitrazepam can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fluvoxamine.
FluvoxamineThe metabolism of Flunitrazepam can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Flunitrazepam can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Flunitrazepam can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Flunitrazepam.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Flunitrazepam.
FospropofolThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fospropofol.
Fusidic AcidThe serum concentration of Flunitrazepam can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Flunitrazepam.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Flunitrazepam.
GemfibrozilThe metabolism of Flunitrazepam can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Flunitrazepam.
GuanfacineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Flunitrazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Flunitrazepam.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Flunitrazepam.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Flunitrazepam.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Flunitrazepam.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Flunitrazepam.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Flunitrazepam.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.
HydroxyzineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Hydroxyzine.
IdelalisibThe serum concentration of Flunitrazepam can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Iloperidone.
ImatinibThe metabolism of Flunitrazepam can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Indalpine.
IndinavirThe metabolism of Flunitrazepam can be decreased when combined with Indinavir.
IrbesartanThe metabolism of Flunitrazepam can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Flunitrazepam.
IsavuconazoniumThe metabolism of Flunitrazepam can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Flunitrazepam.
IsoniazidThe metabolism of Flunitrazepam can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Flunitrazepam can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Flunitrazepam can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Flunitrazepam can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Flunitrazepam.
KetazolamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ketobemidone.
KetoconazoleThe metabolism of Flunitrazepam can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Lamotrigine.
LeflunomideThe metabolism of Flunitrazepam can be decreased when combined with Leflunomide.
LevetiracetamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Flunitrazepam.
LevocabastineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Flunitrazepam.
LevomilnacipranThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Flunitrazepam.
LidocaineThe metabolism of Flunitrazepam can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Lidocaine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Flunitrazepam.
LofentanilThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Lofentanil.
LopinavirThe metabolism of Flunitrazepam can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Flunitrazepam.
LosartanThe metabolism of Flunitrazepam can be decreased when combined with Losartan.
LovastatinThe metabolism of Flunitrazepam can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Flunitrazepam.
Lu AA21004The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Lu AA21004.
LuliconazoleThe serum concentration of Flunitrazepam can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Flunitrazepam can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Flunitrazepam.
MelperoneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Flunitrazepam.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flunitrazepam.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Flunitrazepam.
MetaxaloneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Metaxalone.
MethadoneFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Flunitrazepam.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Flunitrazepam.
MethapyrileneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Flunitrazepam.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Flunitrazepam.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Flunitrazepam.
MethsuximideThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Flunitrazepam.
MetyrosineFlunitrazepam may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Flunitrazepam can be decreased when combined with Mexiletine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Flunitrazepam.
MifepristoneThe metabolism of Flunitrazepam can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.
MirtazapineFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Flunitrazepam.
MitotaneThe serum concentration of Flunitrazepam can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Flunitrazepam can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Flunitrazepam can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Flunitrazepam.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.
NabiloneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Nabilone.
NafcillinThe serum concentration of Flunitrazepam can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Flunitrazepam.
NefazodoneThe metabolism of Flunitrazepam can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Flunitrazepam can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Flunitrazepam can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Flunitrazepam can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Flunitrazepam can be decreased when combined with Nicardipine.
NicotineThe metabolism of Flunitrazepam can be decreased when combined with Nicotine.
NilotinibThe metabolism of Flunitrazepam can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Flunitrazepam.
OlaparibThe metabolism of Flunitrazepam can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Olopatadine.
OmeprazoleThe metabolism of Flunitrazepam can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Flunitrazepam.
OpiumThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Opium.
OrphenadrineFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Flunitrazepam.
OsanetantThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Osanetant.
OsimertinibThe serum concentration of Flunitrazepam can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Flunitrazepam.
OxprenololThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Flunitrazepam.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flunitrazepam.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Flunitrazepam.
PalbociclibThe serum concentration of Flunitrazepam can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Flunitrazepam.
PantoprazoleThe metabolism of Flunitrazepam can be decreased when combined with Pantoprazole.
ParaldehydeFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Flunitrazepam.
ParoxetineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Paroxetine.
ParoxetineThe metabolism of Flunitrazepam can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Flunitrazepam can be increased when it is combined with Peginterferon alfa-2b.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flunitrazepam.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Flunitrazepam.
PerampanelThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Flunitrazepam.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Flunitrazepam.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Flunitrazepam.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Phenoxyethanol.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Flunitrazepam.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Flunitrazepam.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Flunitrazepam.
PipamperoneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Pomalidomide.
PosaconazoleThe metabolism of Flunitrazepam can be decreased when combined with Posaconazole.
PramipexoleFlunitrazepam may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Flunitrazepam.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Flunitrazepam.
PrimidoneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Flunitrazepam.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flunitrazepam.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Flunitrazepam.
PromethazineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Flunitrazepam.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Flunitrazepam.
PropoxycaineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Flunitrazepam is combined with PSD502.
PyrimethamineThe metabolism of Flunitrazepam can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Flunitrazepam can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Flunitrazepam.
QuinineThe metabolism of Flunitrazepam can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ramelteon.
RanolazineThe metabolism of Flunitrazepam can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Flunitrazepam.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Flunitrazepam.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Flunitrazepam.
RifabutinThe metabolism of Flunitrazepam can be increased when combined with Rifabutin.
RifampicinThe metabolism of Flunitrazepam can be increased when combined with Rifampicin.
RifapentineThe metabolism of Flunitrazepam can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Flunitrazepam.
RitonavirThe metabolism of Flunitrazepam can be decreased when combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Romifidine.
RopiniroleFlunitrazepam may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Flunitrazepam can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Flunitrazepam.
RotigotineFlunitrazepam may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Flunitrazepam.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Flunitrazepam can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Flunitrazepam.
SertindoleThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Sertraline.
SertralineThe metabolism of Flunitrazepam can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Flunitrazepam.
SildenafilThe metabolism of Flunitrazepam can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Flunitrazepam can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Flunitrazepam can be increased when it is combined with Simeprevir.
Sodium oxybateFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Flunitrazepam.
SorafenibThe metabolism of Flunitrazepam can be decreased when combined with Sorafenib.
St. John's WortThe serum concentration of Flunitrazepam can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Flunitrazepam.
SulfadiazineThe metabolism of Flunitrazepam can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Flunitrazepam can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Flunitrazepam can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Flunitrazepam.
SuvorexantThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tasimelteon.
TeduglutideThe serum concentration of Flunitrazepam can be increased when it is combined with Teduglutide.
TelaprevirThe metabolism of Flunitrazepam can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Flunitrazepam can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Flunitrazepam.
TenofovirThe metabolism of Flunitrazepam can be decreased when combined with Tenofovir.
TeriflunomideThe serum concentration of Flunitrazepam can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tetrodotoxin.
ThalidomideFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Flunitrazepam.
TheophyllineThe metabolism of Flunitrazepam can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Flunitrazepam.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Flunitrazepam.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Flunitrazepam.
ThiotepaThe metabolism of Flunitrazepam can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tiagabine.
TicagrelorThe metabolism of Flunitrazepam can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Flunitrazepam can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tizanidine.
TocilizumabThe serum concentration of Flunitrazepam can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Flunitrazepam can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Flunitrazepam.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Flunitrazepam.
TrazodoneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Flunitrazepam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flunitrazepam.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Flunitrazepam.
TrimethoprimThe metabolism of Flunitrazepam can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Flunitrazepam.
ValsartanThe metabolism of Flunitrazepam can be decreased when combined with Valsartan.
VemurafenibThe serum concentration of Flunitrazepam can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Flunitrazepam can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Flunitrazepam can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Vilazodone.
VoriconazoleThe metabolism of Flunitrazepam can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Xylazine.
YohimbineThe therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Yohimbine.
ZafirlukastThe metabolism of Flunitrazepam can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Flunitrazepam.
ZiconotideThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Zimelidine.
ZiprasidoneThe metabolism of Flunitrazepam can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Flunitrazepam.
ZonisamideThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Flunitrazepam.
ZotepineThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid taking with grapefruit juice.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Cholesterol binding
Specific Function:
Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in lipid metabolism (PubMed:24814875), but its precise physiological role is controversial. It is apparently not required for steroid hormone biosynthesis. Was initially identified as peripheral-type benz...
Gene Name:
TSPO
Uniprot ID:
P30536
Molecular Weight:
18827.81 Da
References
  1. Katz Y, Weizman R, Weizman A, Gavish M: Disulfiram and diethyldithiocarbamate are competitive inhibitors at the peripheral benzodiazepine receptor. J Pharmacol Exp Ther. 1992 Jul;262(1):394-7. [PubMed:1320691 ]
  2. Papadopoulos V, Berkovich A, Krueger KE, Costa E, Guidotti A: Diazepam binding inhibitor and its processing products stimulate mitochondrial steroid biosynthesis via an interaction with mitochondrial benzodiazepine receptors. Endocrinology. 1991 Sep;129(3):1481-8. [PubMed:1651852 ]
  3. Papadopoulos V, Nowzari FB, Krueger KE: Hormone-stimulated steroidogenesis is coupled to mitochondrial benzodiazepine receptors. Tropic hormone action on steroid biosynthesis is inhibited by flunitrazepam. J Biol Chem. 1991 Feb 25;266(6):3682-7. [PubMed:1847384 ]
  4. Awad M, Gavish M: Solubilization of peripheral-type benzodiazepine binding sites from cat cerebral cortex. J Neurochem. 1989 Jun;52(6):1880-5. [PubMed:2723642 ]
  5. Gandolfo P, Patte C, Leprince J, Thoumas JL, Vaudry H, Tonon MC: The stimulatory effect of the octadecaneuropeptide (ODN) on cytosolic Ca2+ in rat astrocytes is not mediated through classical benzodiazepine receptors. Eur J Pharmacol. 1997 Mar 19;322(2-3):275-81. [PubMed:9098698 ]
  6. Poisnel G, Dhilly M, Le Boisselier R, Barre L, Debruyne D: Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci. 2009 May;110(1):36-46. [PubMed:19443999 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [PubMed:2570451 ]
  4. Oblak AL, Gibbs TT, Blatt GJ: Reduced GABAA receptors and benzodiazepine binding sites in the posterior cingulate cortex and fusiform gyrus in autism. Brain Res. 2011 Mar 22;1380:218-28. doi: 10.1016/j.brainres.2010.09.021. Epub 2010 Sep 19. [PubMed:20858465 ]
  5. You H, Kozuska JL, Paulsen IM, Dunn SM: Benzodiazepine modulation of the rat GABAA receptor alpha4beta3gamma2L subtype expressed in Xenopus oocytes. Neuropharmacology. 2010 Nov;59(6):527-33. doi: 10.1016/j.neuropharm.2010.07.011. Epub 2010 Jul 16. [PubMed:20638393 ]
  6. Skilbeck KJ, O'Reilly JN, Johnston GA, Hinton T: Antipsychotic drug administration differentially affects [3H]muscimol and [3H]flunitrazepam GABA(A) receptor binding sites. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):492-8. Epub 2007 Oct 10. [PubMed:17976880 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Oblak AL, Gibbs TT, Blatt GJ: Reduced GABAA receptors and benzodiazepine binding sites in the posterior cingulate cortex and fusiform gyrus in autism. Brain Res. 2011 Mar 22;1380:218-28. doi: 10.1016/j.brainres.2010.09.021. Epub 2010 Sep 19. [PubMed:20858465 ]
  4. You H, Kozuska JL, Paulsen IM, Dunn SM: Benzodiazepine modulation of the rat GABAA receptor alpha4beta3gamma2L subtype expressed in Xenopus oocytes. Neuropharmacology. 2010 Nov;59(6):527-33. doi: 10.1016/j.neuropharm.2010.07.011. Epub 2010 Jul 16. [PubMed:20638393 ]
  5. Skilbeck KJ, O'Reilly JN, Johnston GA, Hinton T: Antipsychotic drug administration differentially affects [3H]muscimol and [3H]flunitrazepam GABA(A) receptor binding sites. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):492-8. Epub 2007 Oct 10. [PubMed:17976880 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Oblak AL, Gibbs TT, Blatt GJ: Reduced GABAA receptors and benzodiazepine binding sites in the posterior cingulate cortex and fusiform gyrus in autism. Brain Res. 2011 Mar 22;1380:218-28. doi: 10.1016/j.brainres.2010.09.021. Epub 2010 Sep 19. [PubMed:20858465 ]
  4. You H, Kozuska JL, Paulsen IM, Dunn SM: Benzodiazepine modulation of the rat GABAA receptor alpha4beta3gamma2L subtype expressed in Xenopus oocytes. Neuropharmacology. 2010 Nov;59(6):527-33. doi: 10.1016/j.neuropharm.2010.07.011. Epub 2010 Jul 16. [PubMed:20638393 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Santhakumar V, Hanchar HJ, Wallner M, Olsen RW, Otis TS: Contributions of the GABAA receptor alpha6 subunit to phasic and tonic inhibition revealed by a naturally occurring polymorphism in the alpha6 gene. J Neurosci. 2006 Mar 22;26(12):3357-64. [PubMed:16554486 ]
  2. You H, Kozuska JL, Paulsen IM, Dunn SM: Benzodiazepine modulation of the rat GABAA receptor alpha4beta3gamma2L subtype expressed in Xenopus oocytes. Neuropharmacology. 2010 Nov;59(6):527-33. doi: 10.1016/j.neuropharm.2010.07.011. Epub 2010 Jul 16. [PubMed:20638393 ]
  3. Skilbeck KJ, O'Reilly JN, Johnston GA, Hinton T: Antipsychotic drug administration differentially affects [3H]muscimol and [3H]flunitrazepam GABA(A) receptor binding sites. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):492-8. Epub 2007 Oct 10. [PubMed:17976880 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. You H, Kozuska JL, Paulsen IM, Dunn SM: Benzodiazepine modulation of the rat GABAA receptor alpha4beta3gamma2L subtype expressed in Xenopus oocytes. Neuropharmacology. 2010 Nov;59(6):527-33. doi: 10.1016/j.neuropharm.2010.07.011. Epub 2010 Jul 16. [PubMed:20638393 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Thomassin J, Tephly TR: Photoaffinity labeling of rat liver microsomal morphine UDP-glucuronosyltransferase by [3H]flunitrazepam. Mol Pharmacol. 1990 Sep;38(3):294-8. [PubMed:2119476 ]
  2. Cheng Z, Rios GR, King CD, Coffman BL, Green MD, Mojarrabi B, Mackenzie PI, Tephly TR: Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. Toxicol Sci. 1998 Sep;45(1):52-7. [PubMed:9848110 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Tassaneeyakul W, Birkett DJ, Miners JO: Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non-steroidal anti-inflammatory agents. Xenobiotica. 1998 Mar;28(3):293-301. [PubMed:9574817 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Cheng Z, Rios GR, King CD, Coffman BL, Green MD, Mojarrabi B, Mackenzie PI, Tephly TR: Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. Toxicol Sci. 1998 Sep;45(1):52-7. [PubMed:9848110 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A3
Uniprot ID:
P35503
Molecular Weight:
60337.835 Da
References
  1. Cheng Z, Rios GR, King CD, Coffman BL, Green MD, Mojarrabi B, Mackenzie PI, Tephly TR: Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. Toxicol Sci. 1998 Sep;45(1):52-7. [PubMed:9848110 ]
Comments
comments powered by Disqus
Drug created on July 31, 2007 07:10 / Updated on August 17, 2016 12:23